Yao Fen, Yan Shushan, Wang Xiaochen, Shi Denghui, Bai Jianye, Li Feng, Sun Beicheng, Qian Bin
Department of Anesthesiology, Fourth Affiliated Hospital of Nantong University, First Hospital of Yancheng, Yancheng, 224001, Jiangsu Province, China.
Tumour Biol. 2014 Sep;35(9):9061-8. doi: 10.1007/s13277-014-2171-y. Epub 2014 Jun 10.
Previous case-control studies on the association of interleukin-17F (IL-17F) T7488C polymorphism and cancer risk have yielded conflicting and inconclusive findings. We performed a meta-analysis by pooling all currently available data to acquire a more precise estimation of the association. A comprehensive literature screening from the PubMed, Embase, Web of Science, and Wanfang databases was performed for eligible publications without language restrictions. The pooled odds ratios (ORs) with corresponding 95 % confidence intervals (95 % CIs) were calculated. According to the inclusion criteria, a total of nine case-control studies with 3,034 cases and 3,694 controls were included. Overall, the pooled ORs showed that IL-17F T7488C polymorphism was associated with neither increased nor decreased risk of cancer. However, the IL-17F T7488C polymorphism exerted risk effect on cancer in population-based case-control studies when stratifying analysis by source of controls (C vs T OR = 1.24, 95 % CI, 1.10-1.40, pooled OR (POR) < 0.001; TC vs TT OR = 1.28, 95 % CI, 1.11-1.48, POR = 0.001; CC + TC vs TT OR = 1.29, 95 % CI, 1.12-1.48, POR < 0.001). Additionally, the variant genotypes of IL-17F T7488C could alter the risk of gastric cancer under the following comparisons (C vs T OR = 1.29, 95 % CI, 1.13-1.47, POR < 0.001; TC vs TT OR = 1.35, 95 % CI, 1.14-1.60, POR < 0.001; CC + TC vs TT OR = 1.35, 95 % CI, 1.15-1.58, POR < 0.001). Sensitivity analysis by sequential omission of single study did not materially alter the pooled findings. The present meta-analysis suggests that the IL-17F T7488C polymorphism may modify the risk of cancer, particularly gastric cancer. However, the precise association needs to be elucidated by more individual studies with sufficient statistical power.
先前关于白细胞介素-17F（IL-17F）T7488C基因多态性与癌症风险关联的病例对照研究结果相互矛盾且尚无定论。我们通过汇总所有现有数据进行了一项荟萃分析，以获得该关联更精确的估计值。我们对PubMed、Embase、Web of Science和万方数据库进行了全面的文献筛选，纳入符合条件的无语言限制的出版物。计算合并优势比（OR）及相应的95%置信区间（95%CI）。根据纳入标准，共纳入9项病例对照研究，包括3034例病例和3694例对照。总体而言，合并OR显示IL-17F T7488C基因多态性与癌症风险的增加或降低均无关联。然而，在基于人群的病例对照研究中，按对照来源进行分层分析时，IL-17F T7488C基因多态性对癌症有风险效应（C vs T OR = 1.24，95%CI，1.10 - 1.40，合并OR（POR）< 0.001；TC vs TT OR = 1.28，95%CI，1.11 - 1.48，POR = 0.001；CC + TC vs TT OR = 1.29，95%CI，1.12 - 1.48，POR < 0.001）。此外，在以下比较中，IL-17F T7488C的变异基因型可改变胃癌风险（C vs T OR = 1.29，95%CI，1.13 - 1.47，POR < 0.001；TC vs TT OR = 1.35，95%CI，1.14 - 1.60，POR < 0.001；CC + TC vs TT OR = 1.35，95%CI，1.15 - 1.58，POR < 0.001）。通过逐一剔除单个研究进行敏感性分析，并未实质性改变汇总结果。本荟萃分析表明，IL-17F T7488C基因多态性可能会改变癌症风险，尤其是胃癌风险。然而，确切的关联需要更多具有足够统计学效力的个体研究来阐明。
